Human immunodeficiency virus type 1 (HIV-1) derived vectors: Safety considerations and controversy over therapeutic applications

European Journal of Dermatology

Volumn 13, Issue 5, 2003, Pages 424-429

  Romano, Gaetano ^a   Claudio, Pier Paolo ^b   Tonini, Tiziana ^b   Giordano, Antonio ^b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b TEMPLE UNIVERSITY   (United States)

Author keywords

Clinical trials; Gene therapy; Lentiviral vectors; Stem cells

Indexed keywords

ADENOVIRUS VECTOR; COMPLEMENTARY DNA; DRUG CARRIER; LENTIVIRUS VECTOR; MESSENGER RNA; RECOMBINANT RNA; RETROVIRUS VECTOR; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BOVINE IMMUNODEFICIENCY LIKE VIRUS; CLINICAL TRIAL; DRUG SAFETY; EQUINE INFECTIOUS ANEMIA VIRUS; FELINE IMMUNODEFICIENCY VIRUS; GENE EXPRESSION; GENE THERAPY; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; MUTAGENICITY; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PHARMACEUTICAL ENGINEERING; REVIEW; TRANSGENE; VIRAL GENE THERAPY; VIRUS ONCOGENE; VIRUS PATHOGENESIS; VISNA VIRUS;

GENE THERAPY; GENETIC VECTORS; HIV-1; HUMANS; TRANSDUCTION, GENETIC; TREATMENT OUTCOME;

EID: 0142246459     PISSN: 11671122     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (63)

1. Kay MA, Glorioso JC, Naldini L. Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat Med 2001; 7: 33-40.
2. Romano G, Micheli P, Pacilio C, Giordano A. Latest developments in gene transfer technology: achievements, perspectives, and controversies over therapeutic applications. Stem Cells 2000; 18: 19-39.
3. Barker E, Planelles V. Vectors derived from the human immunodeficiency virus, hiv-1. Front Biosci 2003; 8: D491-510.
4. Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, Gage F, Verma IM, Trono D. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996; 272: 263-7.
5. Sirven A, Pflumio F, Zennou V, Titeux M, Vainchenker W, Coulombel L, Dubart-Kupperschmitt A, Charmeau P. The human immunodeficiency virus type-1 central flap is a crucial determinat for lentiviral vector nuclear import and gene transduction of human hematopoietic stem cells. Blood 2000; 96: 4103-10.
6. Follenzi A, Ailles LE, Bakovic S, Geuna M, Naldini L. Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences. Nat Genet 2000; 25: 217-22.
7. Horn PA, Morris JC, Bukovsky AA, Andrews RG, Naldini L, Kurre P, Kiem H-P. Lentivirus-mediated gene transfer into hematopoietic repopulating cells in baboons. Gene Ther 2002; 9: 1464-71.
8. Hamaguci I, Woods N-B, Panagopoulos I, Andersson E, Mikkola H, Fahlman C, Zufferey R, Carlsson L, Trono D, Karlsson S. Lentivirus vector gene expression during ES cell-derived hematopoietic development in vitro. J Virol 2000; 74: 10778-84.
9. Barrette S, Douglas JL, Seidel NE, Bodine DM. Lentivirus-based vectors transduce mouse hematopoietic stem cells with similar efficiency to Moloney leukemia virus-based vectors. Blood 2000; 96: 3385-91.
10. Salmon P, Kinlder V, Ducrey O, Chapuis B, Zubler RH, Trono D. High-level transgene expression in human hematopoietic progenitors and differentiated blood lineages after transduction with improved lentiviral vectors. Blood 2000; 96: 3392-8.
11. Luther-Wyrsch A, Costello E, Thali M, Buetti E, Nissen C, Surbek D, Holzgreve W, Gratwohl A, Tichelli A, Wodnar-Filipowicz. Stable transduction with lentiviral vectors and amplification of immature hematopoietic progenitors from cord blood of preterm human fetuses. Hum Gene Ther 2001; 12: 377-89.
12. Kordower JH, Emborg ME, Bloch J, Ma SY, Chu Y, Leventhal L, McBride J, Chen EY, Palfi S, Roitberg BZ, Brown WD, Holden JE, Pyzalski R, Taylor MD, Carvey P, Ling Z, Trono D, Hantraye P, Deglon N, Aebischer P. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 2000; 290: 767-73.
13. Consiglio A, Quattrini A, Martino S, Bensadoun JC, Dolcetta D, Trojani A, Benaglia G, Marchesini S, Cestari V, Oliverio A, Bordignon C, Naldini L. In vivo gene therapy of metachromatic leukodystrophy by lentiviral vector: corrections of neuropathology and protection against impairments in affected mice. Nat Med 2001; 7: 310-6.
14. Baekelandt V, Claeys A, Eggermont K, Lauwers E, De Strooper B, Nuttin B, Debyser Z. Characterization of lentiviral vector-mediated gene transfer in adult mouse broin. Hum Gene Ther 2002; 13: 841-53.
15. Zennou V, Serguera C, Sarkis C, Colin P, Perret E, Mallet J, Charneau P. The HIV-1 DNA flap stimulates HIV vector-mediated cell transduction in the brain. Nat Biotechnol 2001; 19: 446-50.
16. Galimi F, Noll M, Kanazawa Y, Lax T, Chen C, Grompe M, Verma IM. Gene therapy of Fanconi anemia: preclinical efficacy using lentiviral vectors. Blood 2002; 100: 2732-6.
17. Maurice M, Verhoeyen E, Salmon P, Trono D, Russell SJ, Cosset F-L. Efficient gene transfer into human primary blood lymphocytes by surface-engineered lentiviral vectors that disply a T cell-activating polypeptide. Blood 2002; 99: 2342-50.
18. Chen M, Kasahara N, Keene DR, Chan L, Hoeffler WK, Finlay D, Barkova M, Cannon PM, Mazurek C, Woodley DT. Restoration of type VII collagen expression and function in dystrophic epidermolysis bullosa. Nat Genet 2002; 32: 670-5.
19. Kobinger GP, Weiner DJ, Yu QC, Wilson JM. Filovirus-pseudotyped lentiviral vector can efficiently and stably transduce airway epithelia in vivo. Nat Biotechnol 2001; 19: 225-30.
20. May C, Rivella S, Callegari J, Heller G, Gaensler KM, Luzzatto L, Sadelain M. Therapeutic haemoglobin synthesis in β-tholassaemic mice expressing lentivirus-encoded human β-globin. Nature 2000; 406: 82-6.
21. Tsui LV, Kelly M, Zayek N, Rojas V, Ho K, Ge Y, Moskalenko M, Mondesire J, Davis J, Roey MV, Dull T, McArthur JG. Production of human clotting Factor IX without toxicity in mice after vascular delivery of a lentiviral vector. Nat Biotechnol 2002; 20: 53-7.
22. Frimpong K, Spector SA. Cotransduction of nondividing cells using lentiviral vectors. Gene Ther 2000; 7: 1562-9.
23. Yu D, Chen D, Chiu C, Razmazma B, Chow YH, Pang S. Prostate-specific targeting using PSA promoter-based lentiviral vectors. Cancer Gene Ther 2001; 8: 628-35.
24. Shichinoche T, Bochner BH, Mizutani K, Nishida M, Hegerich-Gilliam S, Naldini L, Kasohara N. Development of lentiviral vectors for antiangiogenic gene delivery. Cancer Gene Ther 2001; 8: 879-89.
25. Gusella GL, Federova E, Hanss B, Marras D, Klotman ME, Klotman PE. Lentiviral gene transduction of kidney. Hum Gene Ther 2002; 13: 407-14.
26. Poeschla E, Corbeau P, Wong-Staal F. Development of HIV vectors for anti-HIV gene therapy. Proc Natl Acad Sci USA 1996; 93: 11395-9.
27. Yang X, Atalar E, Li D, Serfaty JM, Wang D, Kumar A, Cheng L. Magnetic resonance imaging permits in vivo monitoring of catheter-based vascular gene delivery. Circulation 2001; 104: 1588-90.
28. Baek SC, Lin Q, Robbins PB, Fan H, Khavari PA. Sustainable systemic delivery via a single injection of lentivirus into human skin tissue. Hum Gene Ther 2001; 12: 1551-8.
29. Podsakoff GM. Lentiviral vectors approach the clinic but fall back: National Institutes of Health Recombinant DNA Advisory Committee review of a first clinical protocol for use of a lentiviral vector. Mol Ther 2001; 4: 282-3.
30. Dropulic B. Lentivirus in the clinic. To the editor. Mol Ther 2001; 4: 511-2.
31. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, Gross F, Yvon E, Nusbaum P, Selz F, Hue C, Certain S, Casanova JL, Bousso P, Deist FL, Fischer A. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 2000; 288: 669-72.
32. Buckley RH. Gene therapy for human SCID: dreams become reality. Nat Med 2000; 6: 623-4.
33. Marshall E. Gene therapy a suspect in leukemia-like disease. Science 2002; 298: 34-5.
34. Buckley RH. Gene therapy for SCID-a complication after remarkable progress. Lancet 2002; 360: 1185-6.
35. Check E. Second cancer case halts gene-therapy trials. Nature 2003; 421: 305.
36. Romano, G. Gene transfer in experimental medicine. Drug News Perspect (in press).
37. Noguchi P. Risks and benefits of gene therapy. N Engl J Med 2003; 348: 193-4.
38. Rabbitts TH, Bucher K, Chung G, Grutz G, Warren A, Yamada Y. The effect of chromosomal translocations in acute leukemias: the LMO2 paradigm in transcription and development. Cancer Res 1999; 59: Suppl: 1794s-8s.
39. Lemoine NR. Risks ond benefits of gene therapy for immunodeficiency: a reality check. Gene Ther 2002; 9: 1561-2.
40. Zennou V, Petit C, Guetard D, Nerhbass U, Montognier L, Charneau P. HIV-1 genome nuclear impart is mediated by a central DNA flap. Cell 2000; 101: 173-85.
41. Stevenson M. HIV nuclear impart: What's the flap? Nat Med 2000; 6: 626-8.
42. Yu SF, von Ruden T, Kantoff PW, Garber C, Seiberg M, Ruther U, Anderson WF, Wagner EF, Gilboa E. Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells. Proc Natl Acad Sci USA 1986; 83: 3194-8.
43. Berkowitz RD, Ilves H, Plavec I, Veres G. Gene transfer systems derived from Visna virus: analysis of virus production and infectivity. Virology 2001; 279: 116-29.
44. O'Rourke JP, Newbound GC, Kohn DB, Olsen JC, Bunnell BA. Comparison of gene transfer efficiency and gene expression levels achieved with equine infectious anemia virus- and human immunodeficiency virus type 1-derived lentivirus vectors. J Virol 2002; 76: 1510-5.
45. Johnston JC, Gasmi M, Lim LE, Elder JH, Yee JK, Jolly DJ, Campbell KP, Davidson BL, Sauter SL. Minimum requirement for efficient transduction of dividing and nondividing cells by feline immunodeficiency virus vectors. J Virol 1999; 73: 4991-5000.
46. Crystal RG. Bad for cats, good for humans? Modified immunodeficiency virus for gene delivery. J Clin Invest 1999; 104: 1491-3.
47. Matukanis M, Li M, Molina RP, Paszkiet B, Kaleko M, Luo T. Development of second and third generation bovine immunodeficiency virus based gene transfer systems. Hum Gene Ther 2002; 13: 1293-303.
48. Wang G, Slepushkin V, Zabner J, Keshaviee S, Johnston JC, Sauter SL, Jolly DJ, Dubensky TW, Davidson BL, McCray PB. Feline immunodeficiency virus vectors persistently transduce nondividing airway epithelia and correct the cystic fibrosis defect. J Clin Invest 1999; 104: R55-62.
49. Brooks AI, Stein CS, Hughes SM, Heth J, McCray PM, Sauter SL, Johnston JC, Cory-Slechta DA, Federoff HJ, Davidson BL. Functional correction of established central nervous system deficits in an animal model of lysosomal storage disease with feline immunodeficiency virs-based vectors. Proc Natl Acad Sci USA 2002; 99: 6216-21.
50. Lotery AJ, Derksen TA, Russell SR, Mullins RF, Sauter S, Affatigato LM, Stone EM, Davidson BL. Gene transfer to the nonhuman primate retina with recombinant feline immunodeficiency virus vectors. Hum Gene Ther 2002; 13: 689-96
51. Mazarakis ND, Azzouz M, Rohll JB, Ellard FM, Wilkes FJ, Olsen AL, Carter EE, Barber RD, Baban DF, Kingsman SM, Kingsman AJ, O'Malley K, Mitrophanous KA. Rabies virus glycoprotein pseudotyping of lentiviral vectors enables retrograde axonal transport and access to the nervous system after peripheral delivery. Hum Mol Genet 2001; 10: 2109-21.
52. Takahashi K, Luo T., Saishin Y, Saishin Y, Sung J, Hackett S, Brazzell RK, Kaleko M, Campochiaro PA. Sustained transduction of ocular cells with a bovine immunodeficiency viral vector. Hum Gene Ther 13: 1305-16.
53. Yang J, Bogerd HP, Peng S, Wiegand H, Truant R, Cullen BR. An ancient family of human endogenous retroviruses encodes a functional homolog of the HIV-1 Rev protein. Proc Natl Acad Sci USA 1999; 96: 13404-8.
54. Lower R, Lower J, Kurth R. The viruses in all of us: characteristics and biological significance of human endogenous retrovirus sequences. Proc Natl Acad Sci USA 1996; 93: 5177-84.
55. Bogerd HP, Wiegand HL, Yang J, Cullen BR. Mutational definition of functional domains within the Rev homolog encoded by human endogenous retrovirus K. J Virol 2000; 74: 9353-61.
56. Larsson E, Anderson G. Beneficial role of human endogenous retroviruses: facts and hypothesis. Scand J Immunol 1998; 48: 329-38.
57. Pollard V, Malim M. The HIV-1 Rev protein. Annu Rev Microbiol 1998; 52: 491-532.
58. Schneider R, Campbell M, Nasioulas G, Felber BK, Pavlakis GN. Inactivation of the human immunodeficiency virus type 1 inhibitory elements allows Rev-independent expression of gag and Gag/protease and partcle formation. J Virol 1997; 71: 4892-903.
59. Kotsopoulou E, Kim VN, Kingsman AJ, Kingsman SM, Mitrophanous KA. A Rev-independent human immunodeficiency virus type 1 (HIV-1)-based vector that exploits a codon-optimized HIV-1 gag-pol gene. J Virol 2000; 74: 4839-52.
60. Wagner R., Graf M, Bieler K, Wolf H, Grunwald T, Foley P, Uberla K, Rev-independent expression of synthetic gag-pol genes of human immunodeficiency virus type 1 and simian immunodeficiency virus: implications for the safety of lentiviral vectors. Hum Gene Ther 2000; 11: 2403-13.
61. Romano G, Pacilio C, Giordano A. Gene transfer technology in therapy: current applications and future goals. Stem Cells 1999; 17: 191-202.
62. Chen J, Reeves L, Sanburn N, Croop J, Williams DA, Cornetta K. Packaging cell line DNA contamination of vector supernatants: implication for laboratory and clinical research. Virology 2001; 282: 186-97.
63. Ye X, Gao GP, Pabin C, Raper SE, Wilson JM. Evaluating the potential of germ line transmission after intravenous administration of recombinant adenovirus in the C3H mouse. Hum Gene Ther 1998; 9: 2135-42.